Page 54 - Genentech News Today

VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

Epcoritamab, sold as Epkinly, is already approved to treat certain types of large B-cell lymphoma. This article will appear in the January 2024 issue of Evidence-Based Oncology.™

Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion in cash, cash...

Last term, the U.S. Supreme Court did something strange: the Court unanimously affirmed a circuit decision, which had unanimously affirmed a trial court decision. Little about the law seemed ripe for dispute or change, nevertheless, in Amgen v. Sanofi the Supreme Court spoke.

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics company, has entered into a collaboration with Alliance Foundation Trials, LLC for research use of Haystack...

AI adoption and employee well being are top of mind for CHROs.

CHROS are focused on employee well being and AI adoption in 2024.

While 30-years ago biotechnology was a very young industry there is now a broad mix of large companies and smaller providers with candidates.

Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion...

2024 will be a pivotal year for AI Drug Discovery (AIDD). Here are 5 Industry predictions from the industry insider perspective